Opdivo (Nivolumab)

Opdivo (Nivolumab) is a prescription immunotherapy medicine that belongs to a class of drugs known as programmed death receptor-1 (PD-1) inhibitors. It is designed to strengthen the body’s natural immune defenses by blocking the PD-1 pathway, a mechanism that cancer cells often use to evade immune detection. By inhibiting this pathway, Opdivo enables immune cells to recognize and attack cancer cells more effectively.

Opdivo is approved for the treatment of multiple cancer types, including non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (kidney cancer), classical Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, esophageal cancer, gastric cancer, mesothelioma, and several other advanced malignancies. Depending on the indication, it may be used as a single-agent therapy or in combination with other anticancer treatments, including other immunotherapies.

Administered as an intravenous infusion under the supervision of healthcare professionals, Opdivo has demonstrated significant clinical benefits, including improved overall survival and durable treatment responses across a wide range of cancers. Its innovative mechanism of action has made it one of the leading immunotherapy options in oncology, offering hope to patients with advanced and difficult-to-treat diseases.

As a pioneering immune checkpoint inhibitor, Opdivo continues to play a vital role in transforming cancer treatment by providing targeted immune-based therapy that supports better patient outcomes and advances the future of precision oncology.